Chugai deal positions Circadian as "dominant" player in VEGF-D rights
This article was originally published in Scrip
Roche's Japanese subsidiary, Chugai, has granted the Australian bioventure Circadian exclusive worldwide rights to its intellectual property (IP) estate in the area of vascular endothelial growth factor D (VEGF-D).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.